Status:
UNKNOWN
Addition of Enoxaparin to Neoadjuvant Chemoradiation of Esophageal Cancer
Lead Sponsor:
Mashhad University of Medical Sciences
Conditions:
Esophageal Neoplasms
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
This is a randomized, single blind, multi-center, phase two clinical trial. Inclusion criteria are consist of non-metastatic esophageal cancer who are going to receive chemo-radiotherapy. Sample size ...
Detailed Description
This is a randomized, single blind, multi-center, phase two clinical trial. Inclusion criteria are consist of non-metastatic esophageal cancer who are going to receive chemo-radiotherapy. One hundred ...
Eligibility Criteria
Inclusion
- Definitive diagnoses of esophageal squamous cell carcinoma by pathological evaluation
- Non-metastatic esophageal cancer
- Patient who are candidate for chemo-radiation treatment
- Normal complete blood count
- Normal kidney function test
- Normal liver function test
- Normal fasting blood sugar
Exclusion
- Previous history of chest wall radiotherapy
- Previous history of chemotherapy
- Past medical history of Hypertension, diabetes mellitus, renal failure and liver failure
- Pathological report of adenocarcinoma or small cell carcinoma, neoplasm of other organs
- Discontent for the study
- Inability to do daily radiotherapy
- Unwillingness to esophagectomy
Key Trial Info
Start Date :
July 22 2016
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 30 2018
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03254511
Start Date
July 22 2016
End Date
December 30 2018
Last Update
August 22 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mashhad University of Medical Sciences
Mashhad, Khorasan Razavi, Iran, 917751365